{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:14:07Z","timestamp":1787170447510,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40257-022-00754-4","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T14:23:50Z","timestamp":1676989430000},"page":"469-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and Safety of Dupilumab Maintained in Adults \u2265 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-6946","authenticated-orcid":false,"given":"Katrina","family":"Abuabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2822","authenticated-orcid":false,"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-435X","authenticated-orcid":false,"given":"Anna","family":"de Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"B\u00e9go-Le-Bagousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara Rodr\u00edguez","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-5121","authenticated-orcid":false,"given":"Noah A.","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"5","key":"754_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"754_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258219","volume":"16","author":"LN Chan","year":"2021","unstructured":"Chan LN, Magyari A, Ye M, Al-Alusi NA, Langan SM, Margolis D, et al. The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom. PLoS ONE. 2021;16(10): e0258219.","journal-title":"PLoS ONE"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/cea.13784","volume":"51","author":"S De Lusignan","year":"2021","unstructured":"De Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, et al. The epidemiology of eczema in children and adults in England: a population-based study using primary care data. Clin Exp Allergy. 2021;51:471\u201382.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"754_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"754_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","volume":"37","author":"R Tanei","year":"2020","unstructured":"Tanei R. Atopic dermatitis in older adults: a review of treatment options. Drugs Aging. 2020;37(3):149\u201360.","journal-title":"Drugs Aging"},{"issue":"1","key":"754_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","volume":"148","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"754_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","volume":"144","author":"L Zhou","year":"2019","unstructured":"Zhou L, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;144(1):144\u201356.","journal-title":"J Allergy Clin Immunol"},{"issue":"4S","key":"754_CR8","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA, Traidl-Hoffmann C, Lauener R, Sch\u00e4ppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58-64.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"754_CR9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","volume":"8","author":"T Nomura","year":"2020","unstructured":"Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840\u201352.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6 S","key":"754_CR10","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","volume":"112","author":"JM Spergel","year":"2003","unstructured":"Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 S):S118\u201327.","journal-title":"J Allergy Clin Immunol"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:1\u201320.","journal-title":"Ther Adv Chronic Dis."},{"issue":"S1","key":"754_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ggi.12771","volume":"16","author":"R Tanei","year":"2016","unstructured":"Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016;16(S1):75\u201386.","journal-title":"Geriatr Gerontol Int"},{"issue":"2","key":"754_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"754_CR14","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"754_CR15","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore T, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"754_CR16","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 28 Apr 2022."},{"key":"754_CR17","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of product characteristics. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190801145601\/anx_145601_en.pdf. Accessed 28 Apr 2022."},{"issue":"24","key":"754_CR18","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"754_CR19","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"754_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"1","key":"754_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.17791","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, Tha\u00e7i D, Barbarot S, Bagel J, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator\u2019s Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181(1):80\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"754_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","volume":"94","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Simpson EL, Deleuran M, Kataoka M, Chen Z, Gadkari A, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266\u201375.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"754_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"754_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"754_CR25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","volume":"156","author":"M Lam","year":"2020","unstructured":"Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol. 2020;156(11):1240\u20135.","journal-title":"JAMA Dermatol"},{"issue":"22","key":"754_CR26","first-page":"00365","volume":"S0190\u20139622","author":"SA Sreekantaswamy","year":"2022","unstructured":"Sreekantaswamy SA, Tully J, Edelman LS, Supiano MA, Butler D. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis. J Am Acad Dermatol. 2022;S0190\u20139622(22):00365\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"754_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","volume":"304","author":"K Kou","year":"2012","unstructured":"Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res. 2012;304(4):305\u201312.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"754_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","volume":"37","author":"JL Thijs","year":"2017","unstructured":"Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin N Am. 2017;37(1):51\u201361.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"4","key":"754_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174\u201390.","journal-title":"J Allergy Clin Immunol"},{"key":"754_CR30","unstructured":"European Patients\u2019 Academy for Therapeutic Innovation (EUPATI). https:\/\/toolbox.eupati.eu\/glossary\/treatment-emergent-adverse-event. Accessed 28 Apr 2022."},{"issue":"7","key":"754_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14656566.2020.1729738","volume":"21","author":"AN Howell","year":"2020","unstructured":"Howell AN, Ghamrawi RI, Strowd LC, Feldman SR. Pharmacological management of atopic dermatitis in the elderly. Expert Opin Pharmacother. 2020;21(7):761\u201371.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"754_CR32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"754_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","volume":"22","author":"C Patruno","year":"2021","unstructured":"Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581\u20136.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"754_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","volume":"145","author":"T Czarnowicki","year":"2020","unstructured":"Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215\u201328.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"754_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.18652","volume":"182","author":"S Williamson","year":"2020","unstructured":"Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2020;182(1):47\u201354.","journal-title":"Br J Dermatol"},{"key":"754_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/DER.0000000000000845","volume":"3","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Lam M, Flohr C, Thyssen JP, Kabashima K, Bissonnette R, et al. Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and International Eczema Council survey. Dermatitis. 2022;3:200\u20136 (Epub ahead of print).","journal-title":"Dermatitis"}],"updated-by":[{"DOI":"10.1007\/s40257-023-00784-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00754-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T04:51:50Z","timestamp":1684385510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00754-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"20 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-023-00784-6","URL":"https:\/\/doi.org\/10.1007\/s40257-023-00784-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT02277743, NCT02277769, NCT02755649, and NCT02260986. The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. Medical writing and editorial assistance provided by Sandra Dedrick, Ph.D., and Juliet H.A. Bell, Ph.D., of Excerpta Medica, funded by Sanofi and Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jonathan I. Silverberg is an investigator for AbbVie, Celgene, Lilly, GSK, Incyte, LEO Pharma, Realm Therapeutics, Regeneron Pharmaceuticals Inc. and Roche; a consultant for AbbVie, Anacor Pharmaceuticals, Lilly, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, MedImmune, Menlo Therapeutics, Pfizer, Procter & Gamble, Realm Therapeutics, and Regeneron Pharmaceuticals Inc.; and a speaker for Regeneron Pharmaceuticals Inc. and Sanofi. Charles W. Lynde is an advisor, consultant, and speaker for AbbVie, Altius Pharmaceuticals, Amgen, Aralez Pharmaceuticals, Arcutis Biotherapeutics, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher Pharmaceuticals, Dermavant, Lilly, Fresenius Kabi, Galderma, GSK, Innovaderm, Intega Skin Sciences, Janssen, Kyowa Kirin, La Roche-Posay, LEO Pharma, L\u2019Or\u00e9al, Medexus Pharmaceuticals, Merck Group, Pfizer, Procter & Gamble, Pediapharm, Regeneron Pharmaceuticals Inc., Roche, Sanofi, Sentrex Health Solutions, Teva, Tribute Pharmaceuticals, UCB, Valeant, and Viatris. Katrina Abuabara has received personal fees from TARGET-DERM and is an investigator for Pfizer and L\u2019Or\u00e9al. Cataldo Patruno is an investigator, speaker, consultant, and advisory board member for AbbVie, Amgen, Lilly, LEO Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi. Anna De Benedetto is a consultant for dMed and Incyte; has received grant support or clinical trial support from Dermira, Kiniksa Pharmaceuticals, Novartis, and Pfizer. Ryan B. Thomas, Faisal A. Khokhar, and Noah A. Levit are employees and shareholders of Regeneron Pharmaceuticals Inc. Haixin Zhang was an employee of Regeneron Pharmaceuticals Inc., and may have held stock\/stock options in Regeneron Pharmaceuticals Inc. Ainara Rodr\u00edguez Marco and Ga\u00eblle B\u00e9go-Le-Bagousse are employees of Sanofi, and may hold stock and\/or stock options in the company. Jignesh Vakil was an employee of Sanofi at the time of the study, may have held stock and\/or stock options in Sanofi, and is currently an employee at Moderna.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with ethical standards of the responsible committees and the Declaration of Helsinki and with the International Conference on Harmonisation guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. The protocol was reviewed and approved by institutional review boards\/ethics committees at all centers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients or their proxies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no personal patient-related data were used.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Noah A. Levit, Ainara Rodr\u00edguez Marco, and Haixin Zhang. The first draft of the manuscript was written by medical writer Sandra Dedrick, Ph.D., of Excerpta Medica, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this article. Individual anonymized participant data will be considered for sharing once the indication is approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}